SwanBio Therapeutics is a gene therapy company advancing adeno-associated virus (AAV)-based therapies for devastating, inherited neurological conditions, with an initial focus on spinal cord-related disorders. Its lead program, SBT101, is the first clinical-stage AAV-based candidate for adrenomyeloneuropathy (AMN), designed to compensate for the disease-causing ABCD1 mutation. The company plans to dose patients in a Phase 1/2 trial of SBT101 by the end of the year; the program has an FDA-cleared IND and has received Orphan Drug and Fast Track designations. In preclinical studies, SBT101 showed dose-dependent improvement of disease markers and functional benefit in AMN mouse models and was well tolerated in non-human primates at six months. SwanBio is building platform capabilities in delivery and biodistribution, cassette design, and novel capsid development to advance a broader intrathecally delivered pipeline targeting both central and peripheral nervous systems. Financially, the company has raised significant funding to support its R&D expansion, including the recent Series B. SwanBio Therapeutics develops adeno-associated virus (AAV)-based gene therapies aimed at treating AMN and other neurological diseases. The company completed a $52m expanded Series A financing to advance its pipeline. Syncona Ltd. and Partners Innovation Fund contributed $20m as part of the additional commitment to the round. SwanBio plans to use the funds to progress understanding and development of AAV gene therapies, advance manufacturing and development capabilities, and execute a hiring plan to meet pipeline demands. Led by CEO and Director Tom Anderson, the company focuses on the development and commercialization of AAV-based gene therapies for neurological diseases with significant unmet medical need. SwanBio is based in Bala Cynwyd, Pennsylvania, and also has operations in Philadelphia, Pennsylvania and Cambridge, Massachusetts.

Total raised

$108M

Funding rounds

2

Latest round

Series B

Latest activity

May 2022